Several in vitro studies have also investigated targeting TP53 and MDM2 in glioblastoma, emphasizing the necessity of wild-type TP53 for therapeutic efficacy, as certain TP53 variants may accelerate tumor progression or alter treatment responses. This evidence concerns the gene MDM2 and glioblastoma.